Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
Phase 2
Active, not recruiting
NCT03722407
| Condition | Chronic Myelomonocytic Leukemia, Leukemia |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | H. Lee Moffitt Cancer Center and Research Institute |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 29 participants |
|---|
| Interventions | Ruxolitinib |
|---|
| Start date | Aug 28, 2019 |
|---|
| Completion date | Sep 19, 2022 |
|---|
| Results posted | Oct 17, 2023 |
|---|
Summary
This study is to find out if treating Chronic Myelomonocytic Leukemia (CMML) with a study drug (ruxolitinib) can improve outcomes of patients with CMML.
Overall Response
At week 16 · Participants
| Ruxolitinib | 3 Participants |
|---|
| Ruxolitinib | 2 Participants |
|---|
| Ruxolitinib | 20 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.